ArticleMedical sciences (Basel, Switzerland)2026
Real-World Clinical Outcomes of Azacitidine Versus Best Supportive Care in Higher-Risk Myelodysplastic Neoplasms: A Single-Center Cohort Study.
Mihai-Emilian Lapadat, Oana Stanca, Irina Nicoleta Triantafyllidis, Anca Mariana Ciobanu, Nicoleta Mariana Berbec, Cristina Negotei, Cristian Tudor Barta, Ana Maria Bordea, Madalina Marilena Oprea, Andrei Colita
Abstract read
In one paragraphArticle in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Mihai-Emilian LapadatDepartment of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.
Oana StancaDepartment of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.
Irina Nicoleta TriantafyllidisDepartment of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.
Anca Mariana CiobanuClinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania.
Nicoleta Mariana BerbecDepartment of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.
Cristina NegoteiClinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania.
Cristian Tudor BartaDepartment of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.ORCID 0009-0007-9009-5240 Ana Maria BordeaClinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania.
Madalina Marilena OpreaClinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania.
Andrei ColitaDepartment of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antimetabolites, AntineoplasticAzacitidineMyelodysplastic SyndromesAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeAntimetabolites, AntineoplasticAzacitidineazacitidinehigher-risk myelodysplastic neoplasmshypomethylating agentsIPSS-Rleukemic transformationoverall survivalreal-world cohort
Identifiers
PMID42201004
PMCPMC13214720
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390